News
  Date Title View
Sep 17, 2014
- Company to host conference call tomorrow, September 18, 2014 at 9:00 a.m. ET to discuss the clinical hold BURLINGTON, Mass., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed o...
Sep 9, 2014
BURLINGTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent (No. 8828440), entitled "Corticosteroids for the Treatment of Joint Pain," which provides coverage for FX006, the company's lead clinical product candidate....
Sep 3, 2014
- Company to Host Conference Call Tomorrow, September 4, 2014 at 8:30 a.m. EST, During Which Management Will Discuss Updated Timing and Plans BURLINGTON, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Based on a recent meeting with the U.S. Food and Drug Administration (FDA) to review the clinical development program for Flexion's lead drug candidat...
Aug 7, 2014
Recent HighlightsAnnounced positive topline results from Phase 2a synovial fluid pharmacokinetic (PK) study of lead clinical candidate FX006Initiated confirmatory Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis (OA) of the kneeAppointed two new Directors to Flexion BoardRecently announced execution of Southwest Research Ins...
Jul 31, 2014
BURLINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the company will host a conference call and webcast to report its second quarter 2014 financial results on Thursday, August 7, 2014, at 4:30 p.m. ET. The dial-in number for the conference call is toll-free (855) 770-0022 for domest...
Jul 28, 2014
Flexion secures expanded intellectual property for manufacturing of FX006 sustained- release microsphere drug candidate   License includes musculoskeletal disorders and several steroid microsphere combinations BURLINGTON, Mass., July 28, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has executed ...
Jul 24, 2014
- Sandesh (Sandy) Mahatme of Sarepta Therapeutics Appointed New Board Member  - Flexion CEO Michael Clayman Offers Thanks to Departing Board Member Dr. Rafaéle Tordjman  BURLINGTON, Mass., July 24, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today changes to the composition of its Board of Directors. Sandesh...
Jun 17, 2014
- Following intra-articular injection, sustained release of triamcinolone acetonide (TCA) from FX006 maintained therapeutic concentration levels in knee joints of patients through 12 weeks -- Pharmacokinetic (PK) data support previously completed Phase 2b dose-ranging efficacy trial that demonstrated superior magnitude and duration of pain relief o...
Jun 12, 2014
- PathoGenetix President & CEO Ann Merrifield Appointed New Board Member -- Flexion CEO Michael Clayman Offers Thanks to Departing Board Members Bradley Bolzon and Elaine Jones - BURLINGTON, Mass., June 12, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today recent changes to its Board of Directors. Ann Merrifield,...
Jun 11, 2014
BURLINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present at the Wells Fargo Securities Research, Economics & Strategy 2014 Healthcare Conference at 3:00 p.m. Eastern Time on Wednesday, June 18, 2014 at the Intercontinental Hotel in Boston. To acces...
FirstPrevious ...
10
NextLast
= add release to Briefcase